LT3090748T - Kompozicijos, apimančios nukleotido ir oligonukleotido provaistus - Google Patents

Kompozicijos, apimančios nukleotido ir oligonukleotido provaistus

Info

Publication number
LT3090748T
LT3090748T LTEP16158945.2T LT16158945T LT3090748T LT 3090748 T LT3090748 T LT 3090748T LT 16158945 T LT16158945 T LT 16158945T LT 3090748 T LT3090748 T LT 3090748T
Authority
LT
Lithuania
Prior art keywords
nucleotide
compositions
oligonucleotide prodrugs
prodrugs
oligonucleotide
Prior art date
Application number
LTEP16158945.2T
Other languages
English (en)
Inventor
Radhakrishnan Iyer
Seetharamaiyer Padmanabhan
Original Assignee
Spring Bank Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bank Pharmaceuticals, Inc. filed Critical Spring Bank Pharmaceuticals, Inc.
Publication of LT3090748T publication Critical patent/LT3090748T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
LTEP16158945.2T 2005-12-13 2006-12-13 Kompozicijos, apimančios nukleotido ir oligonukleotido provaistus LT3090748T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75003605P 2005-12-13 2005-12-13
US80029406P 2006-05-15 2006-05-15
US11/637,520 US8076303B2 (en) 2005-12-13 2006-12-12 Nucleotide and oligonucleotide prodrugs

Publications (1)

Publication Number Publication Date
LT3090748T true LT3090748T (lt) 2019-08-26

Family

ID=38194676

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16158945.2T LT3090748T (lt) 2005-12-13 2006-12-13 Kompozicijos, apimančios nukleotido ir oligonukleotido provaistus

Country Status (17)

Country Link
US (6) US8076303B2 (lt)
EP (3) EP3090748B1 (lt)
JP (1) JP5044854B2 (lt)
KR (2) KR101248873B1 (lt)
CN (2) CN101437397B (lt)
CY (2) CY1117576T1 (lt)
DK (2) DK3090748T3 (lt)
ES (2) ES2729657T3 (lt)
HR (1) HRP20160531T1 (lt)
HU (2) HUE029190T2 (lt)
IN (1) IN2015DN01786A (lt)
LT (1) LT3090748T (lt)
PL (2) PL3090748T3 (lt)
PT (1) PT3090748T (lt)
RS (1) RS54867B1 (lt)
SI (2) SI1968612T1 (lt)
WO (1) WO2007070598A2 (lt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292973T1 (de) * 2001-01-16 2005-04-15 Can Fite Biopharma Ltd Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
KR101806314B1 (ko) 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
WO2010039543A2 (en) * 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
AU2009323766B2 (en) 2008-12-02 2016-10-06 Wave Life Sciences Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
CN102307889A (zh) * 2008-12-23 2012-01-04 集润德斯股份公司 硫化剂及其用于寡核苷酸合成的用途
AU2015255202B2 (en) * 2009-07-06 2017-07-27 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods of use thereof
IN2012DN00720A (lt) * 2009-07-06 2015-06-19 Ontorii Inc
CN101659612B (zh) * 2009-09-24 2013-01-09 华润赛科药业有限责任公司 一种选择性酯化的方法
WO2012030626A2 (en) * 2010-08-30 2012-03-08 Spring Bank Pharmaceuticals, Inc. Design of oligonucleotide analogs as therapeutic agents
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
KR101327026B1 (ko) 2011-11-29 2013-11-13 현대자동차주식회사 운전자 보호장치
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
AU2013287630B2 (en) 2012-07-13 2017-05-25 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
ES2940887T3 (es) 2012-07-13 2023-05-12 Wave Life Sciences Ltd Método de preparación de oligonucleótidos quirales
EP2956145A4 (en) * 2013-02-18 2016-08-17 Spring Bank Pharmaceuticals Inc DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINATE ADJUVANTIES AND THERAPEUTICS
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
SG10201912897UA (en) * 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design
GB201403697D0 (en) * 2014-03-03 2014-04-16 Link Technologies Ltd Compounds and methods of use
WO2016045642A1 (en) * 2014-09-28 2016-03-31 National Institute Of Biological Sciences, Beijing Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport
WO2016164625A1 (en) * 2015-04-07 2016-10-13 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hcv infection
CA2991156A1 (en) * 2015-07-02 2017-01-05 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
EP3426671A4 (en) * 2016-03-11 2019-11-20 Spring Bank Pharmaceuticals, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
WO2018013908A1 (en) * 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
JOP20170192A1 (ar) * 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
WO2019051489A1 (en) * 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
CN110467646A (zh) * 2018-05-09 2019-11-19 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物
CN110467647B (zh) * 2018-05-09 2022-08-30 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物的制备方法
WO2019219070A1 (zh) * 2018-05-18 2019-11-21 正大天晴药业集团股份有限公司 氘代的低聚核苷酸及前体药物
MX2020012964A (es) 2018-06-01 2021-02-16 Eisai R&D Man Co Ltd Metodos para el tratamiento de cancer de vejiga.
FR3082434B1 (fr) 2018-06-14 2021-04-30 Cairdac Implant cardiaque autonome de type "capsule leadless", comprenant un recuperateur d'energie a lame piezoelectrique
JP6767589B1 (ja) 2018-08-16 2020-10-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 化合物の塩及びそれらの結晶
JP2022509929A (ja) 2018-10-31 2022-01-25 ノバルティス アーゲー Ｓｔｉｎｇアゴニストを含むｄｃ－ｓｉｇｎ抗体コンジュゲート
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
CN113164506B (zh) * 2018-12-06 2023-12-08 正大天晴药业集团股份有限公司 二核苷酸化合物及其前体药物
CN111484540B (zh) * 2019-01-25 2023-09-08 博瑞生物医药（苏州）股份有限公司 含双核苷酸结构的化合物
CN111484541B (zh) * 2019-01-25 2023-06-02 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物及其制备方法
JP7421280B2 (ja) 2019-07-30 2024-01-24 三和シヤッター工業株式会社 建具

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US688183A (en) 1900-12-17 1901-12-03 Carl C Lantz Adjusting-clip for garment-supporters.
DE2817041A1 (de) 1978-04-19 1979-10-31 Reich Maschf Gmbh Karl Verfahren und vorrichtung zum aufteilen von platten
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
ATE193890T1 (de) 1990-04-18 2000-06-15 Procter & Gamble Pharma Antimikrobielle chinolonyl-lactame
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5432165A (en) 1992-04-06 1995-07-11 Oclassen Pharmaceuticals, Inc. Methods for the treatment of infection caused by Hepatitis B virus (HBV)
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
FR2705099B1 (fr) * 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
FR2709754B1 (fr) * 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5581639A (en) 1995-05-04 1996-12-03 National Research Council Of Canada Raman-nath diffraction grating
AU4156197A (en) 1996-08-21 1998-03-06 Hybridon, Inc. Oligonucleotide prodrugs
WO1998017281A1 (en) 1996-10-24 1998-04-30 Vion Pharmaceuticals, Inc. MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CA2599597A1 (en) 1998-08-10 2000-02-24 Idenix (Cayman) Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
JP4294870B2 (ja) 1998-08-10 2009-07-15 インデニックス ファーマシューティカルズ リミティド Ｂ型肝炎の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US20040018150A1 (en) 2000-07-21 2004-01-29 Becker Mark W. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
KR100991975B1 (ko) * 2001-05-16 2010-11-04 미게닉스 인코포레이티드 핵산을 기본으로 하는 화합물 및 이의 사용방법
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN101146337B (zh) 2006-09-15 2011-04-20 华为技术有限公司 新接入节点随机接入的方法及其系统
KR101806314B1 (ko) * 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
KR101123534B1 (ko) 2012-03-13
HUE044034T2 (hu) 2019-09-30
SI1968612T1 (sl) 2016-10-28
HRP20160531T1 (hr) 2016-08-12
KR20110125677A (ko) 2011-11-21
CN101437397A (zh) 2009-05-20
EP1968612B1 (en) 2016-03-09
US20070149462A1 (en) 2007-06-28
KR20080072084A (ko) 2008-08-05
CY1117576T1 (el) 2017-04-26
RS54867B1 (sr) 2016-10-31
WO2007070598A8 (en) 2008-12-31
US20200087338A1 (en) 2020-03-19
PL3090748T3 (pl) 2020-03-31
US20160060287A1 (en) 2016-03-03
HUE029190T2 (en) 2017-02-28
CN102796155B (zh) 2015-08-26
US20140323554A1 (en) 2014-10-30
WO2007070598A9 (en) 2007-11-08
EP1968612A4 (en) 2013-01-09
PL1968612T3 (pl) 2016-11-30
US20120264709A1 (en) 2012-10-18
EP3090748B1 (en) 2019-02-20
US8076303B2 (en) 2011-12-13
US20180273574A1 (en) 2018-09-27
KR101248873B1 (ko) 2013-04-02
JP5044854B2 (ja) 2012-10-10
US10344046B2 (en) 2019-07-09
WO2007070598A2 (en) 2007-06-21
CN102796155A (zh) 2012-11-28
JP2009519345A (ja) 2009-05-14
SI3090748T1 (sl) 2019-09-30
ES2573928T3 (es) 2016-06-13
WO2007070598A3 (en) 2008-10-30
IN2015DN01786A (lt) 2015-07-10
EP3553072A1 (en) 2019-10-16
CN101437397B (zh) 2012-09-05
EP1968612A2 (en) 2008-09-17
US10047114B2 (en) 2018-08-14
DK3090748T3 (da) 2019-05-27
EP3090748A1 (en) 2016-11-09
CY1121639T1 (el) 2020-07-31
ES2729657T3 (es) 2019-11-05
PT3090748T (pt) 2019-06-04
US8691787B2 (en) 2014-04-08
DK1968612T3 (en) 2017-05-22

Similar Documents

Publication Publication Date Title
PT3090748T (pt) Composições compreendendo profármacos de nucleótidos e oligonucleótidos
SG10201400978PA (en) Oligonucleotide analogues incorporating 5-aza-cytosine therein
IL178500A0 (en) Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
EP1723162A4 (en) ANTI-microRNA oligonucleotide molecules
EP1954708A4 (en) METHODS AND COMPOSITIONS IN INTRINSIC GENES
GB0619182D0 (en) Oligonucleotide arrays
EP1963536A4 (en) POLYMERASES FOR INCORPORATING NUCLEOTIDE ANALOGS
PL1856257T3 (pl) Procesy wykorzystujące oligonukleotyd o podwójnej specyficzności oraz oligonukleotyd o podwójnej specyficzności
GB0613796D0 (en) Blower
EP1934837A4 (en) TARGETED ADVERTISING
EP1882392A4 (en) GENES AND THEIR USES FOR PLANT IMPROVEMENTS
EP1850656A4 (en) GENES AND ITS USES FOR THE PLANT PROCESSING OF PLANTS
ZA200902823B (en) Oligoribonucleotides and uses thereof
EP1996730A4 (en) CLEANING OF SMALL RNA
ZA200800228B (en) Nucleotide analogue prodrug and the preparation thereof
ZA200708936B (en) Catalyst compositions
PT1907574E (pt) Oligonucleótidos
EP1885919A4 (en) METHYLATION AND EXPRESSION OF GENES
IL199056A0 (en) Acetaminophen compositions having minimized side effects including reduced hepato-toxicity
EP1908829A4 (en) OLIGONUCLEOTIDE PROBE
GB0524012D0 (en) Multipurpose distribution matrix
GB0615609D0 (en) Uses and compositions comprising miRNAs
GB0421294D0 (en) Bioreductively-activated prodrugs
EP1933874A4 (en) TARGETED BIOZIDS
GB0522578D0 (en) Ribozymal nucleic acid